Q2 2019 Investor Conference Call

Tuesday, July 30, 2019
Start at approx. 2:00 p.m. CEST (12:00 noon UTC)

Investor News July 30, 2019

Second quarter of 2019:

Bayer on track in operational business

Group sales increase by 0.9 percent (Fx & portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx & portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase by 5.9 percent to 1.62 euros / Group outlook confirmed yet increasingly ambitious MORE



Werner Baumann
CEO of
Bayer AG

Audio recording of the investor conference call


Audio file




You can also play the audio recording on your mobile device.


Presentation charts

Half-Year Report 2019


Wolfgang Nickl
CFO of
Bayer AG

Q2 2019 Analyst and Investor Briefing


Q2 2019 All in One Package for Investors and Analysts

Restatements due to PPA of the Monsanto Acquisition